Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9397896 | 0.85 | ALDH1A1 (0.50) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| Hydrochloric Acid SCHEMBL11261613 | 0.82 | ALDH1A1 (0.48) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| SCHEMBL22140387 | 0.82 | ALOX15 (0.46) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| SCHEMBL22680428 | 0.80 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| SCHEMBL208479 | 0.80 | — | — | |
| SCHEMBL527427 | 0.79 | — | — | |
| SCHEMBL17885227 | 0.78 | ALDH1A1 (0.48) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| Bromide SCHEMBL10828447 | 0.78 | — | — | |
| SCHEMBL10189245 | 0.78 | GLO1 (0.52) | ALOX15ALDH1A1LMNAHSD17B10NPSR1 | |
| Hydrochloric Acid SCHEMBL10854392 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ALOX15 554/4885ALDH1A1 527/4885LMNA 2684/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ALOX15 554/4885ALDH1A1 527/4885LMNA 2684/4885 |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ALOX15 554/4885ALDH1A1 527/4885LMNA 2684/4885 |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ALOX15 554/4885ALDH1A1 527/4885LMNA 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.